Dear Editor,
Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) almost all surgical services have been shut down in the newly reorganized COVID‐19 hospitals. In particular, all day‐case procedures, such as exploration under anaesthesia (EUA) for anal fistula, have been postponed.
Symptomatic anal fistula in patients with Crohn’s disease (CD) requires proper and timely treatment in order to avoid perianal sepsis and allow prompt initiation of anti‐TNF‐alpha treatment [1]. Guidelines and clinical recommendations specific for this period of global crisis for inflammatory bowel disease (IBD) suggest that IBD is treated as usual and recommend that any therapy should be administered while minimizing exposure of people and potential transmission [2]. EUA is the accepted gold standard for diagnosis and treatment of anal fistula in CD patients [3]. This operation is generally offered under narcosis in operating theatres but is currently not available in order to try and prevent the exhaustion of resources.
Since 2016, we have offered our CD patients under regular follow‐up with symptomatic anal fistula an ambulatory exploration of the anal canal and rectum (outpatient exploration, OE) in order to reduce waiting times for surgical exploration. OE consists of an examination of the anal canal and lower rectum (proctoscopy) followed by fistula probing, seton insertion and drainage of small abscesses. We have reported a high rate of feasibility (also in complex fistulas) and very high acceptance of the procedure amongst our CD patients [4]. During these past few weeks, we have adopted extra precautions, avoiding the use of electrocautery for the (albeit low) risk of transmission of SARS‐CoV‐2 in the aerosols generated during cauterization and using full personal protective equipment. Furthermore, it has to be said that OE can be accomplished by one surgeon alone, therefore preventing the risk of infection from other healthcare professionals. However, we perform this procedure with the aid of an experienced nurse who provides tremendous help, also reducing most of the patient’s stress.
OE is carried out by a colorectal surgeon with a specific interest in IBD surgery, thus offering our patients not only the chance for timely treatment but also the opportunity to remain in their IBD referral centre and be treated by appropriate specialists instead of receiving suboptimal treatment by a general surgeon in a peripheral but COVID‐free hospital [5]. As for the risk of contagion, OE has specific advantages over EUA, achieved through two mechanisms: (i) minimizing the number of medical personnel required and (ii) avoiding the high‐risk anaesthetic manoeuvres needed for EUA.
While the procedure has already been shown to be feasible and well‐tolerated, the present circumstances have further enhanced both its usefulness and acceptance by patients. We believe that during the COVID‐19 pandemic, OE may represent the best if not the only surgical approach to anal fistulas in CD patients.
A word of caution is needed to emphasize that this procedure has to be implemented in expert, high‐volume IBD centres as this is the only context in which its use would be safe and appropriate.
Funding
No funding was granted for the present work.
Conflicts of interest
The authors negate any conflicts of interest.
Author contributions
All authors have contributed to drafting the work or revising it critically for important intellectual content; approved the final version to be published; agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. DA has performed all operations during the COVID‐19 pandemic and contributed to design. SB has had a major role in conception of the work. GS developed and pioneered the technique used in this work and contributed to conception and design of the present work.
Ethics approval
Ethics approval was not requested.
Patient consent
Informed consent was obtained from all patients.
Permission to reproduce material from other sources
The paper does not reproduce material from other sources.
Clinical trial registration
No registration was obtained.
References
- 1. Lee MJ, Freer C, Adegbola S et al. Patients with perianal Crohn’s fistulas experience delays in accessing anti‐TNF therapy due to slow recognition, diagnosis and integration of specialist services: lessons learned from three referral centres. Color Dis 2018; 1–7. [DOI] [PubMed] [Google Scholar]
- 2. Mao R, Liang J, Shen J et al. Implications of COVID‐19 for patients with pre‐existing digestive diseases. Lancet Gastroenterol Hepatol 2020; 5: 426–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Sica GS, Di CS, Tema G et al. Treatment of peri‐anal fistula in Crohn’ s disease. World J Gastroenterol 2014; 20: 13205–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Sibio S, Di Giorgio A, Campanelli M et al. Ambulatory surgery for perianal Crohn’ s disease: study of feasibility. Gastroenterol Res Pract 2018; 2018: 1–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Keller GPDS, Angriman GMSI, Celentano MCV. Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn’ s disease. Tech Coloproctol 2020; 24: 421–48. [DOI] [PubMed] [Google Scholar]